Scientific article
Open access

Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer's Disease and Neurodegeneration: Old Drugs, New Concerns

Published inFrontiers in oncology, vol. 11, 734881
Publication date2021
First online date2021-12-15

Androgen deprivation therapy (ADT) is a standard treatment for prostate cancer patients, routinely used in the palliative or in the curative setting in association with radiotherapy. Among the systemic long-term side effects of ADT, growing data suggest a potentially increased risk of dementia/Alzheimer's disease in prostate cancer patients treated with hormonal manipulation. While pre-clinical data suggest that androgen ablation may have neurotoxic effects due to Aβ accumulation and increased tau phosphorylation in small animal brains, clinical studies have measured the impact of ADT on long-term cognitive function, with conflicting results, and studies on biological changes after ADT are still lacking. The aim of this review is to report on the current evidence on the association between the ADT use and the risk of cognitive impairment in prostate cancer patients. We will focus on the contribution of Alzheimer's disease biomarkers, namely through imaging, to investigate potential ADT-induced brain modifications. The evidence from these preliminary studies shows brain changes in gray matter volume, cortical activation and metabolism associated with ADT, however with a large variability in biomarker selection, ADT duration and cognitive outcome. Importantly, no study investigated yet biomarkers of Alzheimer's disease pathology, namely amyloid and tau. These preliminary data emphasize the need for larger targeted investigations.

  • Alzheimer’s disease
  • Androgen deprivation therapy
  • Biomarkers
  • Blood
  • Dementia
  • Functional brain imaging
  • Prostate cancer
Citation (ISO format)
ACHARD, Verane et al. Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns. In: Frontiers in oncology, 2021, vol. 11, p. 734881. doi: 10.3389/fonc.2021.734881
Main files (1)
Article (Published version)
ISSN of the journal2234-943X

Technical informations

Creation11/16/2022 12:16:41 PM
First validation07/04/2023 6:42:33 AM
Update time07/04/2023 6:42:33 AM
Status update07/04/2023 6:42:33 AM
Last indexation05/06/2024 4:40:03 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack